Samumed
  • Home
  • About
    • Company
    • Technology
    • Team
    • Careers
    • Contact Us
  • Advisors
  • Patients
  • Pipeline
    • Osteoarthritis of the Knee
    • Oncology – Solid Tumors
    • Androgenetic Alopecia
    • Alzheimer’s Disease
    • Full Pipeline
  • Publications
  • News
Subscribe to Samumed’s newsletter and
media coverage

Sign up below to have the Samumed corporate newsletter and media coverage delivered to your inbox as released. Our corporate newsletter provides regular updates on our therapeutic programs, clinical trials, publications, and company activity.

(*) Required fields.
Missed an issue of our newsletter?
Catch up here
Archive
For media inquiries, please contact Erich Horsley at: media@samumed.com

2020

Date Title
Dec 01 Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology
Nov 17 Samumed Chief Medical Officer, Dr. Yusuf Yazici, Discusses Lorecivivint on the Podcast “ACR on Air”
Jun 01 Michael White, Ph.D. joins Samumed as Chief Scientific Officer
May 22 Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
Jan 23 Rheumatology Advisor: Effect of Intra-Articular Treatment on Patient-Reported Outcomes in Knee Osteoarthritis
Jan 21 BioSpace: Getting to the Root of the Disease: Developing Drugs Against the Hard-to-Target Wnt Pathway
Jan 06 DDNews: Meeting a new mechanism

2019

Date Title
Nov 27 Healio Rheumatology: Lorecivivint yields improved patient-reported outcome scores in knee OA
Nov 14 HCPLive: Lorecivivint a Potential Novel Treatment for Knee Osteoarthritis
Nov 13 Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
Oct 02 Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors
Sep 12 DDNews: A strong showing for SM07883
Aug 15 FierceBiotech: In Conversation with Samumed CEO Osman Kibar: Drugging Wnt, Restoring Youth and Unconventional Capital
Aug 14 Xtalks: Tackling Multiple Pathways with One Alzheimer’s Drug
Aug 05 Technology Networks: Therapeutically Targeting DYRK1A in Alzheimer’s Disease
Jul 24 Alzheimer's News Today: Samumed’s SM07883 Can Prevent Tau-Mediated Neuroinflammation, Neurodegeneration in Mice, Study Shows
Jul 18 Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimer’s Disease
Jun 19 Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis
May 02 Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
Apr 10 Samumed Announces Multiple Presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Apr 10 Alzheimer's News Today: Phase 1 Trial of Alzheimer’s Candidate SM07883 Doses First Participant
Apr 04 Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease
Mar 27 The Rheumatologist: SM04690 Promising for Knee OA
Privacy Policy Terms of use Contact Us © Samumed, LLC. All rights reserved